DanS.GombosMDFACS

Ophthalmology • Houston, TX

Ocular Oncology

Professor & Chief, Section of Ophthalmology MD Anderson Cancer Center

Join to view full profile

Dr. Gombos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gombos' full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Pennsylvania Health System/Scheie Eye InstituteChief Residency, Ophthalmology, 1997 - 1998
University of Pennsylvania Health System/Scheie Eye InstituteResidency, Ophthalmology, 1995 - 1998
Stanford University School of MedicineClass of 1994

Certifications & Licensure

TX State Medical License 2002 - 2026
CA State Medical License 1995 - 2025
OK State Medical License 2020 - 2021
PA State Medical License 1996 - 1998
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2

Publications & Presentations

PubMed

1 citations
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.
Henry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, Jay Chhablani, Ane Bundsbæk Bøndergaard Iversen
Ophthalmology. 2024-11-01
2 citations
15-Gene Expression Profile andas Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1).
J William Harbour, Zelia M Correa, Amy C Schefler, Prithvi Mruthyunjaya, Miguel A Materin
Journal of Clinical Oncology. 2024-10-01
Mineralocorticoid receptor expression and the effects of the mineralocorticoid receptor antagonist spironolactone in a murine model of graft-versus-host disease.
Shinri Sato, Yoko Ogawa, Calvin W Wong, Harrison L Le, Richard W Yee
The Ocular Surface. 2024-10-01

Lectures

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Uveal Melanoma Survivor: Specialized Treatment Saved Both My Eyesight and My LifeDecember 4th, 2019
Genetic Testing Recommended for Children Considered at Risk for Most Common Eye CancerOctober 18th, 2017

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow
American College of Surgeons - ACS
Member